Patents by Inventor Keith Menear
Keith Menear has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10034884Abstract: There is provided a compound of formula I: or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.Type: GrantFiled: June 19, 2017Date of Patent: July 31, 2018Assignee: KuDOS Pharmaceuticals LimitedInventors: Heather Mary Ellen Duggan, Frederic Georges Marie Leroux, Karine Fabienne Malagu, Niall Morrison Barr Martin, Keith Menear, Graeme Cameron Murray Smith
-
Publication number: 20170281637Abstract: There is provided a compound of formula I: or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.Type: ApplicationFiled: June 19, 2017Publication date: October 5, 2017Inventors: Heather Mary Ellen Duggan, Frederic Georges Marie Leroux, Karine Fabienne Malagu, Niall Morrison Barr Martin, Keith Menear, Graeme Cameron Murray Smith
-
Patent number: 9717736Abstract: There is provided a compound of formula I: or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.Type: GrantFiled: June 8, 2015Date of Patent: August 1, 2017Assignee: Kudos Pharmaceuticals LimitedInventors: Heather Mary Ellen Duggan, Frederic Georges Marie Leroux, Karine Fabienne Malagu, Niall Morrison Barr Martin, Keith Menear, Graeme Cameron Murray Smith
-
Publication number: 20160067258Abstract: There is provided a compound of formula I: or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.Type: ApplicationFiled: June 8, 2015Publication date: March 10, 2016Inventors: Heather Mary Ellen Duggan, Frederic Georges Marie Leroux, Karine Fabienne Malagu, Niall Morrison Barr Martin, Keith Menear, Graeme Cameron Murray Smith
-
Patent number: 9102670Abstract: There is provided a compound of formula I: or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.Type: GrantFiled: April 9, 2013Date of Patent: August 11, 2015Assignee: KUDOS PHARMACEUTICALS LIMITEDInventors: Heather Mary Ellen Duggan, Frederic Georges Marie Leroux, Karine Fabienne Malagu, Niall Morrison Barr Martin, Keith Menear, Graeme Cameron Murray Smith
-
Patent number: 8435985Abstract: There is provided a compound of formula I: or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.Type: GrantFiled: November 30, 2011Date of Patent: May 7, 2013Inventors: Keith Menear, Graeme Cameron Murray Smith, Karine Malagu, Heather Mary Ellen Duggan, Niall Morrison Barr Martin, Frederic Georges Marie Leroux
-
Patent number: 8101602Abstract: There is provided a compound of formula I: or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.Type: GrantFiled: January 26, 2011Date of Patent: January 24, 2012Assignee: Kudos Pharmaceuticals, Ltd.Inventors: Keith Menear, Graeme Cameron Murray Smith, Karine Malagu, Heather Mary Ellen Duggan, Niall Morrison Barr Martin, Frederic Georges Marie Leroux
-
Publication number: 20080081809Abstract: There is provided a compound of formula I: , or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.Type: ApplicationFiled: August 21, 2007Publication date: April 3, 2008Applicant: KuDOS Pharmaceuticals LimitedInventors: Heather Duggan, Karine Malagu, Frederic Leroux, Niall Martin, Keith Menear, Graeme Smith
-
Publication number: 20070238731Abstract: A compound of formula I: and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, wherein: R1 and R2 are independently selected from hydrogen, an optionally substituted C1-7 alkyl group, C3-20heterocyclyl group, or C5-20 aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; Q is —NH—C(?O)— or —O—; Y is an optionally substituted C1-5 alkylene group; X is selected from SR3 or NR4R5, wherein, R3 or R4 and R5 are independently selected from hydrogen, optionally substituted C1-7 alkyl, C5-20 aryl, or C3-20 heterocyclyl groups, or R4 and R5 may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; if Q is —O—, X is additionally selected from —C(?O)—NR6R7, wherein R6 and R7 are independently selected from hydrogen, optionally substituted C1-7 alkyl, C5-20 aryl, or C3-20 heterocyclyl groups, oType: ApplicationFiled: September 20, 2005Publication date: October 11, 2007Applicants: KUDOS PHARMACEUTICALS LIMITED, CANCER RESEARCH TECHNOLOGY LIMITEDInventors: Graeme Smith, Niall Martin, Roger Griffin, Bernard Golding, Ian Hardcastle, Kappusamy Saravanan, David Newell, Hilary Calvert, Nicola Curtin, Keith Menear, Marc Hummersone
-
Publication number: 20070093489Abstract: A compound of the formula (I): wherein: A and B together represent an optionally substituted, fused aromatic ring; D is selected from: (i) ?where Y1 is selected from CH and N, Y2 is selected from CH and N, Y3 is selected from CH, CF and N; and (ii) ?and where Q is O or S; RD is: wherein RN1 is selected from H and optionally substituted C1-10 alkyl; X is selected from a single bond, NRN2, CRC3RC4 and C?O; RN2 is selected from H and optionally substituted C1-10 alkyl; RC3 and RC4 are independently selected from H, R, C(?O)OR, where R is optionally substituted C1-10 alkyl, optionally substituted C5-20 aryl or optionally substituted C3-20 heterocyclyl; Y is selected from NRN3 and CRC1RC2; RC1 and RC2 are independently selected from H, R, C(?O)OR, where R is optionally substituted C1-10 alkyl, optionally substituted C5-20 aryl or optionally substituted C3-20 heterocyclyl; RC1 and RC2 together with the carbon atom to which they are attached may form an optionally substituted spiro-fused C5Type: ApplicationFiled: October 17, 2006Publication date: April 26, 2007Applicant: KuDOS Pharmaceuticals LimitedInventors: Muhammad Javaid, Keith Menear, Sylvie Gomez, Marc Hummersone, Niall Martin, Graeme Smith, Xiao-Ling Cockcroft
-
Publication number: 20070049588Abstract: A compound of formula (I): and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, and their use in treating diseases ameliorated by the inhibition of ATM.Type: ApplicationFiled: August 30, 2006Publication date: March 1, 2007Applicant: KuDOS Pharmaceuticals LimitedInventors: Graeme Smith, Niall Martin, Andrew Slade, Keith Menear, Marc Hummersone, Xiao-Ling Cockcroft, Ian Matthews, Laurent Rigoreau, Roger Griffin, David Newell, Nicola Curtin
-
Publication number: 20060264427Abstract: Compounds of formula I: wherein A, B and D are respectively selected from the group consisting of: (i) CH, NH, C; (ii) CH, N, N;and (iii) CH, O, C; the dotted lines represent two double bonds in the appropriate locations; and where Z is selected from S, O, C(?O), CH2 and NH are disclosed for use in inhibiting DNA-PK.Type: ApplicationFiled: April 13, 2006Publication date: November 23, 2006Applicants: KuDOS Pharmaceuticals Limited, Cancer Research Technology LimitedInventors: Graeme Smith, Niall Martin, Keith Menear, Marc Hummersone, Xiao-ling Cockcroft, Mark Frigerio, Roger Griffin, Bernard Golding, Ian Hardcastle, David Newell, HiIary Calvert, Nicola Curtin, Kappusamy Saravanan, Marine Desage-El Murr
-
Publication number: 20060264623Abstract: Compounds of formula l: wherein A, B and D are respectively selected from the group consisting of: (i) CH, NH, C; (ii) CH, N, N;and (iii) CH, O, C; are disclosed for use in inhibiting DNA-PK.Type: ApplicationFiled: April 13, 2006Publication date: November 23, 2006Applicants: KuDOS Pharmaceuticals Limited, Cancer Research Technology LimitedInventors: Graeme Smith, Niall Martin, Keith Menear, Marc Hummersone, Xiao-ling Cockcroft, Mark Frigerio, Roger Griffin, Bernard Golding, Ian Hardcastle, David Newell, Hilary Calvert, Nicola Curtin, Marine Desage-El Murr
-
Publication number: 20060199803Abstract: Compounds of formula l: and isomers, salts, solvates, chemically protected forms, and prodrugs thereof one of X1, X2 and X3 is N, and the others are CH; RN1 and RN2 together with the nitrogen atom to which they are attached form a nitrogen-containing heterocyclic ring having from 4 to 8 ring atoms; RN3 and RN4 together with the nitrogen atom to which they are attached form a nitrogen-containing heterocyclic ring having from 4 to 8 ring atoms and their use in treating diseases ameliorated by the inhibition of mTOR.Type: ApplicationFiled: February 24, 2006Publication date: September 7, 2006Applicant: Kudos Pharmaceuticals LtdInventors: Marc Hummersone, Sylvie Gomez, Keith Menear, Xiao-Ling Cockcroft, Peter Edwards, Ming-lai Loh, Graeme Smith
-
Publication number: 20060199804Abstract: Compounds of formula I: A-B-C??(I) and isomers, salts, solvates, chemically protected forms, and prodrugs thereof wherein: B is selected from the group consisting of: ?where RN is H or Me; or B is a divalent C5 heterocyclic residue containing one or two ring heteroatoms; A is: RA3 and RA5 are independently selected from halo, ORO and RAC, where RO is H or Me, and RAC is H or C1-4 alkyl; XA is selected from N and CRA4, where RA4 is selected from H, ORO, CH2OH, CO2H, NHSO2Me and NHCOMe; RA2 and RA6 are independently selected from H, halo and ORO; or RA3 and RA4 together with the carbon atoms to which they are attached, or RA2 and RA3 together with the carbon atoms to which they are attached, may form a C5-6 heterocylic or heteroaromatic ring, containing at least one nitrogen ring atom; where if X is not N, 1, 2, or 3 of RA2 to RA6 are not H; C is: ?where X is selected from N and CH, Y is selected from N and CH, and Z is selected from N and CRC6; RC3 is selected from H, halo and an optionalType: ApplicationFiled: February 24, 2006Publication date: September 7, 2006Applicant: Kudos Pharmaceuticals LtdInventors: Marc Hummersone, Sylvie Gomez, Keith Menear, Xiao-Ling Cockcroft, Graeme Smith
-
Publication number: 20060178361Abstract: A compound of formula I: and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, wherein: R1 and R2 together form, along with the nitrogen atom to which they are attached, an optionally substituted nitrogen containing heterocyclic ring having from 4 to 8 ring atoms; and R3 is selected from hydroxy and —NRN1RN2, where RN1 and RN2 are independently selected from hydrogen, optionally substituted C1-7 alkyl groups, optionally substituted C3-20 heterocyclyl groups and optionally substituted C5-20 aryl groups, or together form, along with the nitrogen atom to which they are attached, an optionally substituted nitrogen containing heterocyclic ring having from 4 to 8 ring atoms, and its use in inhibiting ATM.Type: ApplicationFiled: February 9, 2006Publication date: August 10, 2006Applicant: Kudos Pharmaceuticals LimitedInventors: Marc Hummersone, Keith Menear, Laurent Rigoreau, Graeme Smith, Niall Martin, Roger Griffin
-
Publication number: 20060149059Abstract: Compounds of the formula (I): wherein A and B together represent an optionally substituted, fused aromatic ring; X can be NRX or CRXRY; if X=NRX then n is 1 or 2 and if X=CRXRY then n is 1; RX is selected from the group consisting of H, optionally substituted C1-20 alkyl, C5-20 aryl, C3-20 heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; RY is selected from H, hydroxy, amino; or RX and RY may together form a spiro-C3-7 cycloalkyl or heterocyclyl group; RC1 and RC2 are both hydrogen, or when X is CRXRY, RC1, RC2, RX and RY, together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; and R1 is selected from H and halo.Type: ApplicationFiled: December 23, 2005Publication date: July 6, 2006Applicants: Kudos Pharmaceuticals Limited, Maybridge LimitedInventors: Niall Martin, Graeme Smith, Stephen Jackson, Vincent Loh, Xiao-Ling Cockcroft, Ian Matthews, Keith Menear, Frank Kerrigan, Alan Ashworth
-
Publication number: 20060135770Abstract: A compound of the formula (I): and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, wherein: R2, R3, R4 and R5 are independently selected from the group consisting of H, C1-7 alkoxy, amino, halo or hydroxy; n is 1 or 2; RN1 and RN2 are independently selected from H and R, where R is optionally substituted C1-10 alkyl, C3-20 heterocyclyl and C5-20 aryl; or RN1 and RN2, together with the nitrogen atom to which they are attached form an optionally substituted 5-7 membered, nitrogen containing, heterocylic ring; Het is selected from: where Y1 and Y3 are independently selected from CH and N, Y2 is selected from CX and N and X is H, Cl or F; and where Q is O or S.Type: ApplicationFiled: December 22, 2005Publication date: June 22, 2006Applicant: Kudos Pharmaceuticals Ltd.Inventors: Muhammad Javaid, Graeme Smith, Niall Martin, Sylvie Gomez, Vincent Loh, Xiao-Ling Cockcroft, Keith Menear
-
Publication number: 20060106025Abstract: A compound of formula I: and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, wherein: R1 and R2 are independently selected from hydrogen, an optionally substituted C1-7 alkyl group, C3-20 heterocyclyl group, or C5-20 aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; Q is —NH—C(?O)— or —O—; Y is an optionally substituted C1-5 alkylene group; X is selected from SR3 or NR4R5, wherein, R3, or R4 and R5 are independently selected from hydrogen, optionally substituted C1-7 alkyl, C5-20 aryl, or C3-20 heterocyclyl groups, or R4 and R5 may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; if Q is —O—, X is additionally selected from —C(?O)—NR6R7, wherein R6 and R7 are independently selected from hydrogen, optionally substituted C1-7 alkyl, C5-20 aryl, or C3-20 heterocyclyl gType: ApplicationFiled: September 20, 2005Publication date: May 18, 2006Applicants: Kudos Pharmaceuticals Limited, Cancer Research Technology LimitedInventors: Graeme Smith, Niall Martin, Keith Menear, Marc Hummersone, Laurent Rigoreau, Roger Griffin, Bernard Golding, David Newell, Hilary Calvert, Nicola Curtin, Ian Hardcastle, Kappusamy Saravanan
-
Publication number: 20060063767Abstract: A compound of formula (I): for use in treating cancer or other diseases ameliorated by the inhibition of PARP, wherein: A and B together represent an optionally substituted, fused aromatic ring; X can be NRX or CRXRY; if X=NRX then n is 1 or 2 and if X=CRXRY then n is 1; RX is selected from the group consisting of H, optionally substituted C1-20 alkyl, C5-20 aryl, C3-20 heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; RY is selected from H, hydroxy, amino; or RX and RY may together form a spiro-C3-7 cycloalkyl or heterocyclyl group; RC1 and RC2 are independently selected from the group consisting of hydrogen and C1-4 alkyl, or when X is CRXRY, RC1, RC2, RX and RY, together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; R1 is selected from H and halo; and Het is selected from: where Y1 is selected from CH and N, Y2 is selected from CH and N, Y3 is selected from CH, CF and N, where only one or two of Y1, Y2 and Y3 can be N; andType: ApplicationFiled: August 26, 2005Publication date: March 23, 2006Applicant: Kudos Pharmaceuticals LtdInventors: Muhammad Javaid, Graeme Smith, Niall Morrison Barr Martin, Sylvie Gomez, Vincent Junior Ming-lai Loh, Xiao-Ling Cockcroft, Stefano Forte, Keith Menear, Ian Timothy William Matthews